Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PNMT | P11086 | 3/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25011732 | 0.89 | GLA (0.45) | GLAPOLBGAATSHRAKR1C3 | |
| SCHEMBL3845967 | 0.87 | GLA (0.42) | GLAPOLBGAATSHRHSD17B1 | |
| SCHEMBL28945489 | 0.83 | S1PR1 (0.43) | GLAPOLBGAATSHRAKR1C3 | |
| SCHEMBL23373938 | 0.83 | GAA (0.40) | GLAPOLBGAATSHRAKR1C3 | |
| SCHEMBL1555044 | 0.82 | NOTUM (0.37) | GLAPOLBGAATSHRPNMT | |
| SCHEMBL10939165 | 0.80 | AR (0.47) | POLBAKR1C3AKR1C2AR | |
| SCHEMBL6058773 | 0.80 | NOTUM (0.35) | GLAPOLBGAATSHRPNMT | |
| SCHEMBL80848 | 0.78 | MPL (0.40) | AR | |
| SCHEMBL29950533 | 0.78 | MPL (0.40) | AR | |
| SCHEMBL17629903 | 0.76 | KIF11 (0.51) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| JP-2001039917-A | PRODUCTION OF 2,2'-BIS(TRIFLUOROMETHYL)-4,4'- BIPHENYLDICARBOXYLIC ACID | SUMITOMO BAKELITE CO LTD | 2001-02-13 | — | — | JP | disclosed |
| US-4628125-A | POLYESTERS, FILMS, FIBERS | POLAROID CORPORATION, PATENT DEPT. (US) | 1986-12-09 | — | — | US | disclosed |
| US-4433132-A | MOLECULAT ORIENTATED FILMS AND FIBERS | POLAROID CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | GLA 1557/4885POLB 1313/4885GAA 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.